Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
NCT ID: NCT00701181
Last Updated: 2012-10-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
184 participants
INTERVENTIONAL
2008-06-30
2011-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Laser
This is a procedure - not a drug intervention.
Laser Treatment
Necessity of laser treatment is assessed every three months.
PF-04523655 (High)
PF-04523655 high
3 mg intravitreal injection
PF-04523655 middle
PF-04523655 middle
1 mg intravitreal injection
PF-04523655 low
PF-04523655 low
0.4 mg intravitreal injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Laser Treatment
Necessity of laser treatment is assessed every three months.
PF-04523655 high
3 mg intravitreal injection
PF-04523655 middle
1 mg intravitreal injection
PF-04523655 low
0.4 mg intravitreal injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects Receiving Concomitant Intravitreal Anti-VEGF Therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Quark Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Meza, Arizona, United States
Pfizer Investigational Site
Peoria, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Mountain View, California, United States
Pfizer Investigational Site
Lakeland, Florida, United States
Pfizer Investigational Site
Winter Haven, Florida, United States
Pfizer Investigational Site
Augusta, Georgia, United States
Pfizer Investigational Site
‘Aiea, Hawaii, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
New Albany, Indiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Henderson, Nevada, United States
Pfizer Investigational Site
Las Vegas, Nevada, United States
Pfizer Investigational Site
Portsmouth, New Hampshire, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
High Point, North Carolina, United States
Pfizer Investigational Site
Statesville, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Rapid City, South Dakota, United States
Pfizer Investigational Site
Corpus Christi, Texas, United States
Pfizer Investigational Site
Glostrup Municipality, , Denmark
Pfizer Investigational Site
Freiburg im Breisgau, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Münster, , Germany
Pfizer Investigational Site
Bhubaneshwar, Odisha, India
Pfizer Investigational Site
Ahmedabad, , India
Pfizer Investigational Site
Bangalore, , India
Pfizer Investigational Site
New Delhi, , India
Pfizer Investigational Site
Kfar Saba, , Israel
Pfizer Investigational Site
Petah Tikva, , Israel
Pfizer Investigational Site
Tel Aviv, , Israel
Pfizer Investigational Site
Tel Litwinsky, , Israel
Pfizer Investigational Site
Ẕerifin, , Israel
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Milan, , Italy
Pfizer Investigational Site
Padua, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Roma, , Italy
Pfizer Investigational Site
Udine, , Italy
Pfizer Investigational Site
Lima, Lima Province, Peru
Pfizer Investigational Site
Frimley, Camberley, Surrey, United Kingdom
Pfizer Investigational Site
Bristol, , United Kingdom
Pfizer Investigational Site
Bristol, , United Kingdom
Pfizer Investigational Site
Liverpool, , United Kingdom
Pfizer Investigational Site
Sheffield, , United Kingdom
Pfizer Investigational Site
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Nguyen QD, Schachar RA, Nduaka CI, Sperling M, Basile AS, Klamerus KJ, Chi-Burris K, Yan E, Paggiarino DA, Rosenblatt I, Aitchison R, Erlich SS; DEGAS Clinical Study Group. Dose-ranging evaluation of intravitreal siRNA PF-04523655 for diabetic macular edema (the DEGAS study). Invest Ophthalmol Vis Sci. 2012 Nov 15;53(12):7666-74. doi: 10.1167/iovs.12-9961.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B0451004
Identifier Type: -
Identifier Source: org_study_id